The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection

Antioxidants and Redox Signaling

Volumn 9, Issue 2, 2007, Pages 169-179

  Weinreb, Orly ^a   Drigues, Noam ^a   Sagi, Yotam ^a   Reznick, Abraham Z ^b   Amit, Tamar ^a   Youdim, Moussa B H ^a,b  

^a Department of Pharmacology   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHAPERONE; CYTOCHROME C OXIDASE; FERRITIN; LADOSTIGIL; NEUROFILAMENT LIGHT PEPTIDE; NEUROFILAMENT PROTEIN; PEROXIREDOXIN; RASAGILINE; UNCLASSIFIED DRUG;

AGE; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENOMICS; HIPPOCAMPUS; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT; REGULATOR GENE; SYNAPTOGENESIS;

AGING; ANIMALS; BRAIN; GENE EXPRESSION PROFILING; GENOMICS; HIPPOCAMPUS; INDANS; IRON; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTEOMICS; RATS; RATS, WISTAR;

RATTUS;

EID: 33846253429     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.9.169     Document Type: Article

References (88)

1. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, and Youdim MBH. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives in vivo. J Neurochem 89: 1119-1125, 2004.
2. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4: 3943-3952, 2004.
3. Beer I, Barnea E, Ziv T, and Admon A. Improving large-scale proteomics by clustering of mass spectrometry data. Proteomics 4: 950-960, 2004.
4. Berton F, Iborra C, Boudier JA, Seagar MJ, and Marqueze B. Developmental regulation of synaptotagmin I, II, III, and IV mRNAs in the rat CNS. J Neurosci 17: 1206-1216, 1997.
5. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, and Landfield PW. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23: 3807-3819, 2003.
6. Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, Porter NM, and Landfield PW. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res Rev 4: 481-512, 2005.
7. Butterfield DA, Boyd-Kimball D, and Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86: 1313-1327, 2003.
8. Butterfield DA and Poon HF. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol 40: 774-783, 2005.
9. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, and Youdim MBH. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585, 2000.
10. Chandrasekaran K, Hatanpaa K, Rapoport SI, and Brady DR. Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Brain Res Mol Brain Res 44: 99-104, 1997.
11. Chen W, Ji J, Xu X, He S, and Ru B. Proteomic comparison between human young and old brains by two-dimensional gel electrophoresis and identification of proteins. Int J Dev Neurosci 21: 209-216, 2003.
12. Connor JR, Snyder BS, Arosio P, Loeffler DA, and LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 65: 717-724, 1995.
13. Dassler K, Zydek M, Wandzik K, Kaup M, and Fuchs H. Release of the soluble transferrin receptor is directly regulated by binding of its ligand ferritransferrin. J Biol Chem 281: 3297-3304, 2006.
14. De Iuliis A, Grigoletto J, Recchia A, Giusti P, and Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin Chim Acta 357: 202-209, 2005.
15. Freed WJ and Vawter MP. Microarrays: applications in neuroscience to disease, development, and repair. Restor Neurol Neurosci 18: 53-56, 2001.
16. Galvin JE and Ginsberg SD. Expression profiling in the aging brain: a perspective. Ageing Res Rev 4: 529-547, 2005.
17. Geldenhuys WJ, Gaasch KE, Watson M, Allen DD, and Van der Schyf CJ. Optimizing the use of open-source software applications in drug discovery. Drug Discov Today 11: 127-132, 2006.
18. Gelinas S, Chapados C, Beauregard M, Gosselin I, and Martinoli MG. Effect of oxidative stress on stability and structure of neurofilament proteins. Biochem Cell Biol 78: 667-674, 2000.
19. George AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, and Li QX. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 27: 614-623, 2006.
20. Golden TR and Melov S. Microarray analysis of gene expression with age in individual nematodes. Aging Cell 3: 111-124, 2004.
21. Golden TR and Melov S. Mitochondrial DNA mutations, oxidative stress, and aging. Mech Ageing Dev 122: 1577-1589, 2001.
22. Gotz ME, Kunig G, Riederer P, and Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122, 1994.
23. Grasbon-Frodl EM, Kosel S, Sprinzl M, von Eitzen U, Mehraein P , and Graeber MB. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics 2: 121-127, 1999.
24. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, and Youdim MBH. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573, 2004.
25. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, and Riederer P. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216-1223, 1995.
26. Itoh K, Weis S, Mehraein P, and Muller-Hocker J. Cytochrome c oxidase defects of the human substantia nigra in normal aging. Neurobiol Aging 17: 843-848, 1996.
27. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, and Youdim MBH. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2: 327-340, 1990.
28. Jellinger KA, Kienzl E, Rumpelmaier G, Paulus W, Riederer P, Stachelberger H, Youdim MBH, and Ben-Shachar D. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 60: 267-272, 1993.
29. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13: 24-34, 1998.
30. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 136: 6-15, 1991.
31. Jin MH, Lee YH, Kim JM, Sun HN, Moon EY, Shong MH, Kim SU, Lee SH, Lee TH, Yu DY, and Lee DS. Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett 381: 252-257, 2005.
32. Kadenbach B, Huttemann M, Arnold S, Lee I, and Bender E. Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic Biol Med 29: 211-221, 2000.
33. Kern A, Roempp B, Prager K, Walter J, and Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem 281: 2405-2413, 2006.
34. Kim NH, Jeong MS, Choi SY, and Hoon Kang J. Oxidative modification of neurofilament-L by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Biochimie 86: 553-559, 2004.
35. Kong J and Xu Z. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Neurosci Lett 281: 72-74, 2000.
36. Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, and Pirttila T. Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis 20: 858-870, 2005.
37. Lawler JM and Demaree SR. Relationship between NADP-specific isocitrate dehydrogenase and glutathione peroxidase in aging rat skeletal muscle. Mech Ageing Dev 122: 291-304, 2001.
38. Lazarov O, Peterson LD, Peterson DA, and Sisodia SS. Expression of a familial Alzheimer's disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex. J Neurosci 26: 429-434, 2006.
39. Lenaz G, Bovina C, D'Aurelio M, Fato R, Formiggini G, Genova ML, Giuliano G, Merlo Pich M, Paolucci U, Parenti Castelli G, and Ventura B. Role of mitochondria in oxidative stress and aging. Ann NY Acad Sci 959: 199-213, 2002.
40. Lin H, Zhai J, and Schlaepfer WW. RNA-binding protein is involved in aggregation of light neurofilament protein and is implicated in the pathogenesis of motor neuron degeneration. Hum Mol Genet 14: 3643-3659, 2005.
41. Liu H, Tarima S, Borders AS, Getchell TV, Getchell ML, and Stromberg AJ. Quadratic regression analysis for gene discovery and pattern recognition for non-cyclic short time-course microarray experiments. BMC Bioinformatics 6: 106, 2005.
42. Maruyama W, Akao Y, Carrillo M, Kitani K, Youdium M, and Naoi M. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24: 675-682, 2002.
43. Maruyama W, Takahashi T, Youdim MBH, and Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109: 467-481, 2002.
44. Maruyama W, Weinstock M, Youdim MB, Nagai M, and Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]- ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341: 233-236, 2003.
45. Melov S and Hubbard A. Microarrays as a tool to investigate the biology of aging: a retrospective and a look to the future. Sci Aging Knowledge Environ 2004: re7, 2004.
46. Miller RM and Federoff HJ. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 11: 539-549, 2005.
47. Mirnics K and Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci 7: 434-439, 2004.
48. Mufson EJ, Counts SE, and Ginsberg SD. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res 27: 1035-1048, 2002.
49. Nadon R and Shoemaker J. Statistical issues with microarrays: processing and analysis. Trends Genet 18: 265-271, 2002.
50. Norgren N, Rosengren L, and Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 987: 25-31, 2003.
51. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 40: suppl 32-37; discussion 37-39., 1990.
52. Olanow CW and Youdim MB. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, and Youdim MB, editors. Neurodegeneration and Neuroprotection in Parkinson's Disease, Academic Press Edition. London; 1996. pp. 55-69.
53. Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, Eriksson PS, Blennow K, and Davidsson P. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res 71: 526-533, 2003.
54. Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, De Marco C, and Butterfield DA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice - a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 38: 960-968, 2005.
55. Pletcher SD, Macdonald SJ, Marguerie R, Certa U, Stearns SC, Goldstein DB, and Partridge L. Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol 12: 712-723, 2002.
56. Poon HF, Calabrese V, Calvani M, and Butterfield DA. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid Redox Signal 8: 381-394, 2006.
57. Poon HF, Calabrese V, Scapagnini G, and Butterfield DA. Free radicals and brain aging. Clin Geriatr Med 20: 329-359, 2004.
58. Poon HF, Vaishnav RA, Butterfield DA, Getchell ML, and Getchell TV. Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes. J Neurochem 94: 380-392, 2005.
59. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet 2: 418-427, 2001.
60. Rhee SG, Kim KH, Chae HZ, Yim MB, Uchida K, Netto LE, and Stadtman ER. Antioxidant defense mechanisms: a new thiol-specific antioxidant enzyme. Ann NY Acad Sci 738: 86-92, 1994.
61. Riederer P, Janetzky B, Gerlach M, Reichmann H, Mandel S, and Youdim MBH. Parkinson's disease, iron mitochondria, inflammatory responses, and oxidative stress: prospects for neuroprotection. Neurscience News 2: 83-87, 1999,
62. Rose MR, Mueller LD, and Long AD. Pharmacology, genomics, and the evolutionary biology of ageing. Free Radic Res 36: 1293-1297, 2002.
63. Sagi Y, Mandel S, Amit T, and Youdim MBH. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in MPTP-induced Parkinsonism. Neurobiol Dis, 2006 (in press).
64. Sandberg R, Yasuda R, Pankratz DG, Carter TA, Del Rio JA, Wodicka L, Mayford M, Lockhart DJ, and Barlow C. Regional and strain-specific gene expression mapping in the adult mouse brain. Proc Natl Acad Sci USA 97: 11038-11043, 2000.
65. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, and Richards JG. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62: 15-30, 1994.
66. Schena M. Genome analysis with gene expression microarrays. Bioessays 18: 427-431, 1996.
67. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, and McGeer PL. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 21: 503-510, 2000.
68. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, and Castro JL. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39: 8698-8704, 2000.
69. Shin SJ, Lee SE, Boo JH, Kim M, Yoon YD, Kim SI, and Mook-Jung I. Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics 4: 3359-3368, 2004.
70. Soreghan BA, Lu BW, Thomas SN, Duff K, Rakhmatulin EA, Nikolskaya T, Chen T, and Yang AJ. Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease. J Alzheimers Dis 8: 227-241, 2005.
71. Ting JT, Kelley BG, and Sullivan JM. Synaptotagmin IV does not alter excitatory fast synaptic transmission or fusion pore kinetics in mammalian CNS neurons. J Neurosci 26: 372-380, 2006.
72. Vetrivel KS and Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66: S69-73, 2006.
73. Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, Siani V, Benson MD, Calvas P, Miravalle L, Rascol O, and Delisle MB. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol 63: 363-380, 2004.
74. Wang G, Zhang Y, Chen B, and Cheng J. Preliminary studies on Alzheimer's disease using cDNA microarrays. Mech Ageing Dev 124: 115-124, 2003.
75. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, and Youdim MB. Novel Neuroprotective mechanism of action of rasagiline is associated with Its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann NY Acad Sci 1053: 348-355, 2005.
76. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, and Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18: 1471-1473, 2004.
77. Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg J, and Youdim MBH. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm [Suppl] 60: S157-S170, 2000.
78. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MBH, and Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann NY Acad Sci 939: 148-161., 2001.
79. Weiss C, Zeng Y, Huang J, Sobocka MB, and Rushbrook JI. Bovine NAD+-dependent isocitrate dehydrogenase: alternative splicing and tissue-dependent expression of subunit 1. Biochemistry 39: 1807-1816, 2000.
80. Westermeier R and Marouga-R. Protein detection methods in proteomics research. Biosci Rep 25: 19-32, 2005.
81. Witke W, Sutherland JD, Sharpe A, Arai M, and Kwiatkowski DJ. Profilin I is essential for cell survival and cell division in early mouse development. Proc Natl Acad Sci USA 98: 3832-3836, 2001.
82. Yates III JR, Eng JK, McCormack AL, and Schieltz D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem 67: 1426-1436, 1995.
83. Yokota S, Yanagi H, Yura T, and Kubota H. Cytosolic chaperonin-containing t-complex polypeptide 1 changes the content of a particular subunit species concomitant with substrate binding and folding activities during the cell cycle. Eur J Biochem 268: 4664-4673, 2001.
84. Youdim MBH and Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27-35, 2005.
85. Youdim MBH. Deficiency and excess of iron in brain function and dysfunction. Nutr Rev 59: S83-85; discussion S85-87, 2001.
86. Youdim MBH. Rasagiline: an anti-Parkinson drug with neuroprotective activity. Future Drugs 3: 737-749, 2003.
87. Youdim MBH, Stephenson G, and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 1012: 306-325, 2004.
88. Zecca L, Youdim MB, Riederer P, Connor JR, and Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873, 2004.